CHANG Jian,ZHANG Yu-Tong,WANG Li-Zhe et al. Management of refractory neuroblastoma with high-dose topotecan plus cyclophosphamide and vincristine[J]. CJCP, 2014, 16(2): 120-123.
Simon T, Langle A, Harnischmacher U, et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of highrisk neuroblastoma. Results of a phase-Ⅱ trial[J]. J Cancer Res Clin Oncol, 2007, 133(9): 653-661.
[2]
Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using apharmacokinetically guided dosing approach[J]. J Clin Oncol, 2005, 23(18): 4039-4047.
[3]
Brisse HJ, McCarvile MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project[J]. Radiology, 2011, 261(1): 243-257.
[4]
Mueller S, Matthay KK. Neuroblastoma: biology and staging[J]. Curr Oncol Rep, 2009, 11(6): 431-438.
[5]
Berthold F, Hero B, Kremens B, et al. Long-term results and risk profiles of patients in five consecutive trials(1979-1997) with stage 4 neuroblastoma over 1 year of age[J]. Cancer Lett, 2003, 197(1-2): 11-17.
[6]
Broeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment[J]. J Clin Oncol, 1993, 11(8): 1466-1477.
[7]
Kushner BH, Kramer K, Modak S, et al. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma[J]. Cancer, 2010, 116(12): 3054-3060.
Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines[J]. J Natl Cancer Inst, 1996, 88(11): 734-741.
[11]
Carol H, Houghton PJ, Morton CL, et al. Initial testing of topotecan by the pediatric preclinical testing program[J]. Pediatr Blood Cancer, 2010, 54(5): 707-715.
[12]
Kretschmar CS, Kletzel M, Murray K, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase Ⅱ investigational window: a pediatric oncology group study[J]. J Clin Oncol, 2004, 22(20): 4119-4126.
[13]
Simon T, Langler A, Berthold F, et al. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial[J]. J Pediatr Hematol Oncol, 2007, 29(2): 101-106.
[14]
London WB, Frantz CN, Campbell LA, et al. Phase Ⅱ randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study[J]. J Clin Oncol, 2010, 28(24): 3808-3815.
[15]
De Ioris MA, Castellano A, Ⅱari I, et al. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma[J]. Eur J Cancer, 2011, 47(4): 572-578.
[16]
Thompsn J, George EO, Poquette CA, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts[J]. Clin Cancer Res, 1999, 5(11): 3617-3631.
